Posted by 
Seysara (sarecycline), a new class tetracycline-derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. It is an oral tablet that is taken once daily with or without food.
It has proven significant reduction of inflammatory lesions after three weeks of treatment and is generally safe and well tolerated. It represents an innovative treatment for patients with moderate to severe acne.
Acne vulgaris is a common chronic skin disease involving blockage and inflammation of pilosebaceous units (hair follicles and their accompanying sebaceous gland). Acne is an inflammatory lesions affecting the face, back and chest. According to the Global Burden of Disease (GBD) study, acne vulgaris affects 85% of young adults aged 12–25 years globally.
Seysara has proven to be a safe and effective treatment in two 12-week multicenter, randomized, double-blind, placebo-controlled studies. The use of Seysara during tooth development may cause permanent discoloration of the teeth. Central nervous system side effects, including light-headedness, dizziness and vertigo.